Nigeria: NAFDAC Vows to Implement Pharmaceutical Traceability Strategy to Tackle Substandard Drugs

30 January 2023

The National Agency for Food and Drug Administration and Control, NAFDAC, has vowed to confront the menace of substandard and falsified medicines in the country with the implementation of a pharmaceutical traceability strategy with a view to safeguarding the health of the Nigerian populace.

The Director General, of the Agency, Prof. Mojisola Adeyeye, who dropped the hint at the Traceability workshop in Port Harcourt, Rivers State, said the onerous task of safeguarding the health of the nation is daunting in the face of the chaotic drug distribution system currently existing in Nigeria.

She emphasised that the falsification and diversion of health commodities carry very serious health and economic consequences.

In a statement signed by the NAFDAC Resident Media Consultant in Lagos, Mr Sayo Akintola, Adeyeye reiterated that NAFDAC had developed a 5-Year Traceability Implementation plan in line with the objectives of the Nigeria Pharmaceutical Traceability Strategy to achieve supply chain visibility and strengthen interventions against substandard and falsified medicines by the end of her second term.

She said the development, gazetting, and dissemination of the Traceability of Pharmaceutical products Regulations is essential for the adoption and enforcement of the provisions of the Nigeria Pharmaceutical Traceability Strategy.

The Regulation, accompanied by guidelines and compliance requirements would provide a legal framework to support advocacy for stakeholders to implement traceability in the distribution of pharmaceuticals or supply chains.

Further, Adeyeye noted that the participation of relevant stakeholders during the drafting of the Traceability Regulation is important to ensure understanding among stakeholders of the provisions and to welcome feedback, with the goal of improving compliance.

A major achievement in the direction of reducing the incidence of Substandard and Falsified medicines in the country was the hosting of the second Africa GSI Traceability Conference on Healthcare in Lagos in September 2019.

The Conference attracted Medicines Regulatory Agencies from about twenty-five countries in Africa, as well as other stakeholder partners from the Americas and Europe. The Agency is already on a five-year roadmap to establishing a culture of Track & Trace with regards to pharmaceutical products.

With this, Adeyeye said that medicines and medical devices can be monitored throughout the supply chain from manufacturing to the end user, the patient, adding that the Agency has developed a roadmap to this effect which has been approved by the Honourable Minister of Health.

She disclosed that the traceability strategy document was the outcome of the year' (1919/2020) work by NAFDAC in collaboration with the Ministry of Health, USAID, and GS1 Technologies. The NAFDAC Traceability Office. governance and current funding were subsequently supported by international partners such as USAID, World Bank, World Health Organisation; Bill and Melinda Gates Foundation, and Global Fund. All these have resulted in an enabling environment for the implementation of the track and trace of medical commodities using global standards.

Describing the gains of implementing pharmaceutical traceability as enormous, Adeyeye said traceability would provide visibility of medicines from plant to patient to promote trust in the pharmaceutical sector and healthcare system.

AllAfrica publishes around 500 reports a day from more than 100 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.

Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.